Mural Oncology spins out from Alkermes with $275M and a lead immunotherapy program

Katherine Lewin

News Reporter

Mural Oncology is spinning out of Alkermes with $275 million and a lead immunotherapy candidate already in two studies in mucosal melanoma and ovarian cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Mural Oncology spins out from Alkermes with $275M and a lead immunotherapy program

Katherine Lewin

News Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Regeneron plans to buy 23andMe for $256M

David Liu, Sam Sternberg unveil new way to insert big genes in human cells

Prime Medicine sidelines only clinical program, replaces CEO and lays off some staff

Intellia's CRISPR therapy likely causes 'permanent' gene knockdown in ATTR amyloidosis

Exclusive: CellCentric collects $120M to treat multiple myeloma with a capsule

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Mur­al On­col­o­gy spins out from Alk­er­mes with $275M and a lead im­munother­a­py pro­gram

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Mural Oncology spins out from Alkermes with $275M and a lead immunotherapy program